[go: up one dir, main page]

EP4070785A1 - Lyophilized composition of copanlisib salt - Google Patents

Lyophilized composition of copanlisib salt Download PDF

Info

Publication number
EP4070785A1
EP4070785A1 EP21166992.4A EP21166992A EP4070785A1 EP 4070785 A1 EP4070785 A1 EP 4070785A1 EP 21166992 A EP21166992 A EP 21166992A EP 4070785 A1 EP4070785 A1 EP 4070785A1
Authority
EP
European Patent Office
Prior art keywords
solution
copanlisib
salt
glycine
trehalose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP21166992.4A
Other languages
German (de)
French (fr)
Other versions
EP4070785B1 (en
Inventor
designation of the inventor has not yet been filed The
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Priority to EP21166992.4A priority Critical patent/EP4070785B1/en
Priority to CA3214098A priority patent/CA3214098A1/en
Priority to US18/553,911 priority patent/US20240082253A1/en
Priority to PCT/EP2022/058763 priority patent/WO2022214400A1/en
Publication of EP4070785A1 publication Critical patent/EP4070785A1/en
Application granted granted Critical
Publication of EP4070785B1 publication Critical patent/EP4070785B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes

Definitions

  • the presented invention relates to a lyophilized pharmaceutical formulation comprising:
  • the presented invention relates to a lyophilized pharmaceutical formulation comprising:
  • the copanlisib salt is preferably hydrochloride salt or dihydrochloride salt or hydrogen phosphate salt or malate salt.
  • the formulation optionally comprises glycine.
  • the ratio between the bulking agent selected from trehalose or lactose and glycine can be between 2: 5 to 5: 2 (parts by weight), said ratios of excipients being calculated on the anhydrous basis and the sum of the parts by weight of the sugar component and glycine is 7.
  • Tg'-modifer glass transition temperature modifier
  • the weight ratio between the copanlisib salt and the bulking agent can be between 1:2 and 1:2.5, preferably between 1:2.1 and 1:2.3.
  • the weight ratio between copanlisib or a salt thereof and sum of the bulking agent and glycine can be between 1:2 and 1:2.5, preferably between 1:2.2 and 1:2.4.
  • the bulking agent selected from lactose or trehalose can be used either in an anhydrous form or in a hydrated form.
  • Trehalose is preferably used as trehalose dihydrate
  • lactose is preferably used as lactose monohydrate.
  • the presented invention further relates to a pharmaceutical solution comprising:
  • the pharmaceutical solution further optionally comprises glycine.
  • the concentration of copanlisib salt thereof in the solution is preferably 30 mg/ml (calculated on copanlisib as a base).
  • the salt of copanlisib is preferably hydrochloride salt or dihydrochloride salt or hydrogen phosphate salt or malate salt.
  • the copanlisib salt is formed in situ during the manufacturing process by contacting copanlisib with an acid in the solvent.
  • the bulking agent selected from lactose or trehalose can be used either in an anhydrous form or in a hydrated form.
  • Trehalose is preferably used as trehalose dihydrate
  • lactose is preferably used as lactose monohydrate.
  • the weight ratio between copanlisib salt and the bulking agent can be between 1:2 and 1:2.5, preferably between 1:2.1 and 1:2.3.
  • the concentration of trehalose (calculated as anhydrous form) in the pharmaceutical solution can be between 62.5 mg/ml and 72.5 mg/ml, preferably it is 67.5 mg/ml.
  • the concentration of lactose (calculated as anhydrous form) in the pharmaceutical solution can be between 58.5 mg/ml and 68.5 mg/ml, preferably it is 63.2 mg/ml.
  • the ratio between the bulking agent and glycine can be between 2: 5 to 5: 2 (parts by weight), said ratios of excipients being calculated on the anhydrous basis and the sum of the parts by weight of the sugar component and glycine is 7 and the weight ratio between copanlisib or a salt thereof and the sum of the bulking agent and glycine can be between 1:2 and 1:2.5, preferably between 1:2.2 and 1:2.4.
  • the concentration of trehalose (calculated as anhydrous form) or lactose (calculated as anhydrous form) in the pharmaceutical solution can be between 20 mg/ml and 70 mg/ml.
  • the concentration of glycine in the pharmaceutical solution can be between 30 mg/ml and 60 mg/ml, preferably it is between 40 mg/ml and 50 mg/ml.
  • the solvent is preferably water, more preferably water for injection.
  • pH of the solution can be adjusted for example 2 M aqueous sodium hydroxide solution.
  • pH of the solution is adjusted to pH greater than 5.5, preferably to pH between 5.5 and 5.7.
  • the pharmaceutical solution can be further processed to a lyophilized dosage forms suitable for parenteral administration after reconstitution.
  • the presented invention further relates to a process for preparation of lyophilized pharmaceutical formulation comprising:
  • the process steps are preferably performed under a protective atmosphere, for example using nitrogen or argon.
  • the salt can be selected from copanlisib salt with hydrochloric acid or phosphoric acid (H 3 PO 4 ) or malic acid.
  • the suitable solvent is preferably water. pH of the solution is preferably adjusted to pH between 5.5 and 5.7.
  • the formulation can optionally comprising glycine.
  • copanlisib salt is prepared "in situ" by contacting copanlisib base with an acid in the solvent.
  • of lyophilized pharmaceutical formulation comprising:
  • the pharmaceutical formulation can optionally comprising glycine.
  • the process steps are preferably performed under a protective atmosphere, for example using nitrogen or argon.
  • the concentration of copanlisib base in the solvent is preferably 30 mg/ml.
  • the acid can be selected form hydrochloric acid or phosphoric acid (H 3 PO 4 ) or malic acid.
  • the acid can be added in a form of a solution of the acid in the suitable solvent.
  • the molar ratio between copanlisib base and the hydrochloric acid can be between1:2 and 1:2.4.
  • the molar ratio between copanlisib and phosphoric acid (H 3 PO 4 ) or malic acid can be between 1:1 and 1:1.3.
  • the mixture is then stirred for between 10 and 60 minutes to obtain a solution.
  • the suitable solvent is preferably water.
  • pH of the solution is preferably adjusted to pH higher than 5.5, more preferably to pH between 5.5 and 5.7, advantageously with sodium hydroxide water solution (for example 2M solution).
  • the pharmaceutical solution for lyophilization preferably contains:
  • the concentration of the bulking agent in the pharmaceutical solution is preferably:
  • the concentration of bulking agent trehalose or lactose is preferably between 20 mg/ml and 30 mg/ml (calculated on trehalose anhydrous form or lactose anhydrous form) and the ratio between the bulking agent and glycine can be between 2: 5 to 5: 2 (parts by weight), said ratios of excipients being calculated on the anhydrous basis and the sum of the parts by weight of the sugar component and glycine is 7.
  • the prepared pharmaceutical solution can be further processed to lyophilized injectable dosage forms as described in Examples or by a process comprising:
  • the lyophilized formulation according to presented invention can be used for treatment conditions treatable by copanlisib or a salt thereof.
  • composition of the pharmaceutical solution is a composition of the pharmaceutical solution:
  • Solution was filtered using a 0.22-micron syringe filter (PVDF), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 1.71 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • PVDF 0.22-micron syringe filter
  • concentration of formed solution is 15 mg/ml of Copanlisib base.
  • Example 2 Lyophilized formulation comprising Copanlisib dihydrochloride and trehalose
  • composition of the pharmaceutical solution is a composition of the pharmaceutical solution:
  • pH of the solution was then adjusted using 2M NaOH to pH 5.57. Volume was made up to 50 mL with WFI.
  • concentration of formed solution is 15 mg/ml of Copanlisib base.
  • Example 3 Lyophilized formulation comprising Copanlisib dihydrochloride and lactose
  • composition of the pharmaceutical solution is a composition of the pharmaceutical solution:
  • pH of the solution was then adjusted using 2M NaOH to pH 5.69. Volume was made up to 50 mL with WFI.
  • concentration of formed solution is 15 mg/ml of Copanlisib base.
  • Example 4A, 4B, 4C Lyophilized formulation comprising copanlisib dihydrochloride, trehalose or lactose, glycine
  • composition of pharmaceutical solutions :
  • Example 4A Example 4B Example 4C Copanlisib base 30 mg/ml 30 mg/ml 30 mg/ml Glycine 70 mg/ml 50 mg/ml 50 mg/ ml Trehalose - 20 mg /ml - Lactose - - 20 mg/ml
  • Example 4A 1728 mg of copanlisib dihydrochloride were mixed with 3500 mg of glycine and 30 ml of water for injection (WFI) previously bubbled with nitrogen for 20 minutes. The mixture was stirred for 15 min at 400 rpm until dissolution. Yellow solution was formed.
  • WFI water for injection
  • pH of the solution was then adjusted using 2M NaOH to pH 5.60. Volume was made up to 50 mL with WFI. pH of the solution was 5.45, therefore pH was readjusted by 2 M NaOH solution to pH 5.60.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 4A Start 5°C/72h Sum of impurities (% IN) 1.24 1.16
  • Example 4B 1728 mg of copanlisib dihydrochloride was mixed with 2500 mg of glycine, 1110 mg of trehalose dihydrate and 30 ml of water for injection (WFI) previously bubbled with nitrogen for 20 minutes. The mixture was stirred at 400 rpm for 15 minutes until dissolution. Yellow solution was formed.
  • WFI water for injection
  • pH of the solution was then adjusted using 2M NaOH to pH 5.61. Volume was made up to 50 mL with WFI. pH was readjusted by 2 M NaOH solution to 5.60.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 4B Start 5°C/72h Sum of impurities (% IN) 1.24 1.22
  • Example 4C 1728 mg of copanlisib dihydrochloride was mixed with 2500 mg of glycine, 1050 mg of lactose monohydrate and 30 ml of water for injection (WFI) previously bubbled with nitrogen for 20 minutes. The mixture was stirred at 400 rpm for 15 minutes until dissolution. Yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.60. Volume was made up to 50 mL with WFI. pH was readjusted by 2 M NaOH solution to 5.57.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 4C Start 5°C/72h Sum of impurities (% IN) 1.24 1.21
  • Vials prepared according to Examples 4A, 4B and 4C were loaded in in the lyophilization chamber and lyophilized using Epsilon 2-6D according to following program: No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar) 1 Precooling/Loading +20 Atm. 2 Freezing 2:00 -45 Atm. 3 Freezing 1:30 -45 Atm. 4 Freezing 1:00 -10 Atm. 5 Annealing 4:00 -10 Atm. 6 Freezing 1:10 -45 Atm. 7 Freezing 1:30 -45 Atm. 8 Main Drying 0:10 -45 0.100 9 Main Drying 4:00 -5 0.100 10 Main Drying 20:30 -5 0.100 11 Secondary Drying 5:00 +35 0.100 12 Secondary Drying 6:00 +35 0.100
  • concentration of formed solution is 15 mg/ml of Copanlisib base.
  • Example 4A Glycine Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Example 4C Lactose+Glycine Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Examples 5A, 5B, 5C Lyophilized formulation comprising copanlisib hydrogenphosphate, trehalose or lactose, glycine
  • composition of pharmaceutical solutions :
  • Example 5A Example 5B Example 5C Copanlisib base 30 mg/ml 30 mg/ml 30 mg/ml Glycine 70 mg/ml 50 mg/ml 50 mg/ ml Trehalose - 20 mg /ml - Lactose - - 20 mg/ml
  • Example 5A 1500 mg of copanlisib base was mixed with 3500 mg of Glycine and 20 mL of water for injection (WFI). 5 ml Phosphoric acid (H 3 PO 4 ) in form of diluted solution (88 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed.
  • WFI water for injection
  • pH of the solution was then adjusted using 2M NaOH to pH 5.63. Volume was made up to 50 mL with WFI, pH was not changed.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 5A Start 5°C/72h Sum of impurities (% IN) 1.12 1.04
  • Example 5B 1500 mg of copanlisib base was mixed with 2500 mg of Glycine, 1110 mg of trehalose dihydrate and 20 mL of water for injection (WFI). 5 ml of Phosphoric acid in form of diluted solution (88 mg/ml in water) was added. The mixture was stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed. pH of the solution was then adjusted using 2M NaOH to pH 5.67. Volume was made up to 50 mL with WFI.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 5B Start 5°C/72h Sum of impurities (% IN) 1.12 1.07
  • Example 5C 1500 mg of Copanlisib base was mixed with 2500 mg of Glycine, 1050 mg of Lactose monohydrate and 20 mL of water for injection (WFI). 5 ml of Phosphoric acid in form of diluted solution (88 mg/ml in water) was added and the mixture stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.63. Volume was made up to 50 mL with WFI.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution. Pharmaceutical solution 5C Start 5°C/72h Sum of impurities (% IN) 1.12 1.10
  • Vials prepared according to Examples 5A, 5B and 5C were loaded in the lyophilization chamber and lyophilized using Christ Epsilon 2-6D according to following program: No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar) 1 Precooling/Loading +20 Atm. 2 Freezing 2:00 -45 Atm. 3 Freezing 1:30 -45 Atm. 4 Freezing 1:00 -10 Atm. 5 Annealing 4:00 -10 Atm. 6 Freezing 1:10 -45 Atm. 7 Freezing 2:30 -45 Atm. 8 Main Drying 0:10 -45 0.100 9 Main Drying 4:00 -5 0.100 10 Main Drying 20:30 -5 0.100 11 Secondary Drying 5:00 +35 0.100 12 Secondary Drying 6:00 +35 0.100
  • concentration of formed solution is 15 mg/ml of Copanlisib base.
  • Example 5A Glycine Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Examples 6A, 6B, 6C Lyophilized formulation comprising copanlisib malate, trehalose or lactose, glycine
  • composition of pharmaceutical solutions :
  • Example 6A Example 6B Example 6C Copanlisib base 30 mg/ml 30 mg/ml 30 mg/ml Glycine 70 mg/ml 50 mg/ml 50 mg/ ml Trehalose - 20 mg /ml - Lactose - - 20 mg/ml
  • Example 6A 1500 mg of Copanlisib base was mixed with 3500 mg of Glycine and 20 mL of water for injection (WFI). 5ml of Malic acid in form of diluted solution (97 mg/ml in water) was added and the mixture stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.63. Volume was made up to 50 mL with WFI. pH was readjusted by 2 M NaOH solution to 5.61.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 6A Start 5°C/72h Sum of impurities (% IN) 1.12 1.15
  • Example 6B 1500 mg of copanlisib base was mixed with 2500 mg of Glycine, 1110 mg of Trehalose dihydrate and 20 mL of water for injection (WFI). 5 ml of Malic acid in form of diluted solution (97 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Pale yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.64. Volume was made up to 50 mL with WFI.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 6B Start 5°C/72h Sum of impurities (% IN) 1.09 1.03
  • Example 6C 1500 mg of Copanlisib base was mixed with 2500 mg of Glycine, 1050 mg of Lactose monohydrate and 20 mL of water for injection (WFI). 5 ml of Malic acid in form of diluted solution (97 mg/ml in water) was added and the mixture stirred for 15 minutes at 400 rpm until dissolution. Pale yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.67. Volume was made up to 50 mL with WFI.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 6C Start 5°C/72h Sum of impurities (% IN) 1.12 1.04
  • Vials prepared according to Examples 6A, 6B and 6C were loaded in in the lyophilization chamber and lyophilized using Christ Epsilon 2-6D according to following program: No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar) 1 Precooling/Loading +20 Atm. 2 Freezing 2:00 -45 Atm. 3 Freezing 1:30 -45 Atm. 4 Freezing 1:00 -10 Atm. 5 Annealing 4:00 -10 Atm. 6 Freezing 1:10 -45 Atm. 7 Freezing 2:30 -45 Atm. 8 Main Drying 0:10 -45 0.100 9 Main Drying 4:00 -5 0.100 10 Main Drying 20:30 -5 0.100 11 Secondary Drying 5:00 +35 0.100 12 Secondary Drying 6:00 +35 0.100
  • concentration of formed solution is 15 mg/ml of Copanlisib base.
  • Example 6A Glycine Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Example 6C Lactose+Glycine Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Examples 7A, 7B Lyophilized formulation comprising copanlisib hydrogenphosphate, trehalose or lactose, glycine
  • composition of pharmaceutical solutions :
  • Example 7A Example 7B Copanlisib base 30 mg/ml 30 mg/ml Glycine 40 mg/ml 40 mg/ ml Trehalose 30 mg /ml - Lactose - 30 mg/ml
  • Example 7A 1500 mg of copanlisib base was mixed with 2000 mg of Glycine, 1665 mg of Trehalose dihydrate and 20 mL of water for injection (WFI). 5 ml of Phosphoric acid (H3PO4) in form of diluted solution (88 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed.
  • WFI water for injection
  • pH of the solution was then adjusted using 2M NaOH to pH 5.64. Volume was made up to 50 mL with WFI.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 7A Start 5°C/72h Sum of impurities (% IN) 1.09 1.06
  • Example 7B 1500 mg of copanlisib base was mixed with 2000 mg of Glycine, 1575 mg of Lactose and 20 mL of water for injection (WFI). 5 ml of Phosphoric acid in form of diluted solution (88 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed. pH of the solution was then adjusted using 2M NaOH to pH 5.66. Volume was made up to 50 mL with WFI.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 7B Start 5°C/72h Sum of impurities (% IN) 1.09 1.07
  • Vials prepared according to 7A and 7B were loaded in in the lyophilization chamber and lyophilized using Christ Epsilon 2-6D according to following program: No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar) 1 Precooling/Loading +20 Atm. 2 Freezing 2:00 -45 Atm. 3 Freezing 1:30 -45 Atm. 4 Freezing 1:00 -10 Atm. 5 Annealing 4:00 -10 Atm. 6 Freezing 1:10 -45 Atm. 7 Freezing 2:30 -45 Atm. 8 Main Drying 0:10 -45 0.100 9 Main Drying 4:00 -5 0.100 10 Main Drying 20:30 -5 0.100 11 Secondary Drying 5:00 +35 0.100 12 Secondary Drying 6:00 +35 0.100
  • concentration of formed solution is 15 mg/ml of Copanlisib base.
  • Example 7A Trehalose+Glycine Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Example 7B Lactose+Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Example 8A, 8B Lyophilized formulation comprising copanlisib malate, trehalose or lactose, glycine
  • composition of pharmaceutical solutions :
  • Example 8A Example 8B Copanlisib base 30 mg/ml 30 mg/ml Glycine 40 mg/ml 40 mg/ ml Trehalose 30 mg /ml - Lactose - 30 mg/ml
  • Example 8A 1500 mg of copanlisib base was mixed with 2000 mg of Glycine and 1665 mg of trehalose dihydrate and 20 mL of water for injection (WFI). 5 ml of Malic acid in form of diluted solution (97 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Pale yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.68. Volume was made up to 50 mL with WFI.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 8A Start 5°C/72h Sum of impurities (% IN) 1.09 1.05
  • Example 8B 1500 mg of Copanlisib base was mixed with 2000 mg of Glycine, 1575 mg of Lactose monohydrate and 20 mL of water for injection (WFI). 5 ml of Malic acid in form of diluted solution (97 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Pale yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.71. Volume was made up to 50 mL with WFI.
  • the pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
  • Pharmaceutical solution 8B Start 5°C/72h Sum of impurities (% IN) 1.09 1.10
  • Vials prepared according to 8A and 8B were loaded in in the lyophilization chamber and lyophilized using Christ Epsilon 2-6D according to following program: No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar) 1 Precooling/Loading +20 Atm. 2 Freezing 2:00 -45 Atm. 3 Freezing 1:30 -45 Atm. 4 Freezing 1:00 -10 Atm. 5 Annealing 4:00 -10 Atm. 6 Freezing 1:10 -45 Atm. 7 Freezing 2:30 -45 Atm. 8 Main Drying 0:10 -45 0.100 9 Main Drying 4:00 -5 0.100 10 Main Drying 20:30 -5 0.100 11 Secondary Drying 5:00 +35 0.100 12 Secondary Drying 6:00 +35 0.100
  • concentration of formed solution is 15 mg/ml of Copanlisib base.
  • Example 8A Trehalose+Glycine Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Example 8B Lactose+Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • stabilities of formulation comprising glycine only are much worse that stabilities of formulation comprising glycine and trehalose or lactose (EX 5B, EX 5C, EX 6B, EX 6C).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The presented invention relates to a lyophilized pharmaceutical formulation comprising copanlisib salt and a bulking agent selected from lactose or trehalose and to a process for preparation thereof.

Description

    BRIEF DESCRIPTION OF THE PRESENT INVENTION
  • The presented invention relates to a lyophilized pharmaceutical formulation comprising:
    1. a. Copanlisib salt;
    2. b. A bulking agent selected from lactose or trehalose;
    and to a process for preparation thereof. DETAILED DESCRIPTION OF THE PRESENT INVENTION
  • The presented invention relates to a lyophilized pharmaceutical formulation comprising:
    1. a. Copanlisib salt;
    2. b. A bulking agent selected from lactose or trehalose;
    and to a process for preparation thereof.
  • The copanlisib salt is preferably hydrochloride salt or dihydrochloride salt or hydrogen phosphate salt or malate salt.
    The formulation optionally comprises glycine. The ratio between the bulking agent selected from trehalose or lactose and glycine can be between 2: 5 to 5: 2 (parts by weight), said ratios of excipients being calculated on the anhydrous basis and the sum of the parts by weight of the sugar component and glycine is 7.
  • Glycine as Tg'-modifer (glass transition temperature modifier) capable of modifying a sufficiently Tg' of the pharmaceutical solution to higher temperatures and therefore improves the economy of process for preparation of the formulation.
  • The weight ratio between the copanlisib salt and the bulking agent can be between 1:2 and 1:2.5, preferably between 1:2.1 and 1:2.3. In the case both the bulking agent and glycine are used, the weight ratio between copanlisib or a salt thereof and sum of the bulking agent and glycine can be between 1:2 and 1:2.5, preferably between 1:2.2 and 1:2.4.
  • The bulking agent selected from lactose or trehalose can be used either in an anhydrous form or in a hydrated form. Trehalose is preferably used as trehalose dihydrate, lactose is preferably used as lactose monohydrate.
  • It has been surprisingly found that the use of lactose or trehalose provides better stability than other bulking agents disclosed in the prior art. Comparative trials have been performed against mannitol and glycine among others bulking agents, the results are disclosed in Examples 1 to 8.
  • In comparison with the formulation disclosed in WO2019/048527 , the formulation of the presented invention has following advantages:
    1. 1. Better stability of the formulation;
    2. 2. Mannitol as a bulking agent can be risky due to the danger of vial breaking. There is no such risk when trehalose or lactose is used;
    3. 3. If mannitol crystallizes after lyophilization, it releases the associated water back into the already dried material, which accelerates the destabilization of the water sensitive drug. There is no such risk associated with use of when trehalose or lactose;
    4. 4. The formulation of presented invention shows good stability and solubility at pH higher than 5.5. WO2019/048527 shows in the examples that a pH higher than 5 is not suitable for the preparation of a pharmaceutical (bulk) solution, in particular in view of the possible precipitation of the dissolved material.
  • The presented invention further relates to a pharmaceutical solution comprising:
    1. 1. Copanlisib salt;
    2. 2. A bulking agent selected from trehalose or lactose;
    3. 3. A solvent.
  • The pharmaceutical solution further optionally comprises glycine.
  • The concentration of copanlisib salt thereof in the solution is preferably 30 mg/ml (calculated on copanlisib as a base). The salt of copanlisib is preferably hydrochloride salt or dihydrochloride salt or hydrogen phosphate salt or malate salt. In a preferred embodiment of the invention the copanlisib salt is formed in situ during the manufacturing process by contacting copanlisib with an acid in the solvent.
  • The bulking agent selected from lactose or trehalose can be used either in an anhydrous form or in a hydrated form. Trehalose is preferably used as trehalose dihydrate, lactose is preferably used as lactose monohydrate.
  • The weight ratio between copanlisib salt and the bulking agent (calculated as anhydrous form) can be between 1:2 and 1:2.5, preferably between 1:2.1 and 1:2.3. The concentration of trehalose (calculated as anhydrous form) in the pharmaceutical solution can be between 62.5 mg/ml and 72.5 mg/ml, preferably it is 67.5 mg/ml. The concentration of lactose (calculated as anhydrous form) in the pharmaceutical solution can be between 58.5 mg/ml and 68.5 mg/ml, preferably it is 63.2 mg/ml.
  • In the case glycine is used the ratio between the bulking agent and glycine can be between 2: 5 to 5: 2 (parts by weight), said ratios of excipients being calculated on the anhydrous basis and the sum of the parts by weight of the sugar component and glycine is 7 and the weight ratio between copanlisib or a salt thereof and the sum of the bulking agent and glycine can be between 1:2 and 1:2.5, preferably between 1:2.2 and 1:2.4. The concentration of trehalose (calculated as anhydrous form) or lactose (calculated as anhydrous form) in the pharmaceutical solution can be between 20 mg/ml and 70 mg/ml. The concentration of glycine in the pharmaceutical solution can be between 30 mg/ml and 60 mg/ml, preferably it is between 40 mg/ml and 50 mg/ml.
  • The solvent is preferably water, more preferably water for injection.
  • pH of the solution can be adjusted for example 2 M aqueous sodium hydroxide solution. Preferably, pH of the solution is adjusted to pH greater than 5.5, preferably to pH between 5.5 and 5.7.
  • The pharmaceutical solution can be further processed to a lyophilized dosage forms suitable for parenteral administration after reconstitution.
  • It has been surprisingly found that the stability of the prepared solutions remains unchanged for at least 72 hours, which is particularly advantageous for the industrial production of injectable dosage forms. The tested solutions remained clear and without precipitation for the indicated time. Also, the stability of the drug products prepared according to examples shows a significant improvement in terms of purity compared to the formulations disclosed in WO2019/048527 as is presented in Example 7.
  • The presented invention further relates to a process for preparation of lyophilized pharmaceutical formulation comprising:
    1. a. Copanlisib salt;
    2. b. A bulking agent selected form lactose or trehalose;
    and optionally glycine, the process comprising:
    1. 1. Mixing the copanlisib salt with the bulking agent in a suitable solvent;
    2. 2. Stiring the mixture to obtain a solution;
    3. 3. Adjusting pH of the solution;
    4. 4. Lyophilization of the solution.
  • The process steps are preferably performed under a protective atmosphere, for example using nitrogen or argon. The salt can be selected from copanlisib salt with hydrochloric acid or phosphoric acid (H3PO4) or malic acid. The suitable solvent is preferably water. pH of the solution is preferably adjusted to pH between 5.5 and 5.7. The formulation can optionally comprising glycine.
  • In a preferred embodiment of the invention the copanlisib salt is prepared "in situ" by contacting copanlisib base with an acid in the solvent. In the preferred embodiment of the invention the of lyophilized pharmaceutical formulation comprising:
    1. a. Copanlisib salt;
    2. b. A bulking agent selected form lactose or trehalose;
    is prepared by a process comprising:
    1. 1. Mixing the copanlisib base with the bulking agent in a suitable solvent;
    2. 2. Adding the acid;
    3. 3. Stirring the mixture to obtain a solution;
    4. 4. Adjustting pH of the solution;
    5. 5. Lyophilization of the solution.
  • The pharmaceutical formulation can optionally comprising glycine. The process steps are preferably performed under a protective atmosphere, for example using nitrogen or argon. The concentration of copanlisib base in the solvent is preferably 30 mg/ml. The acid can be selected form hydrochloric acid or phosphoric acid (H3PO4) or malic acid. The acid can be added in a form of a solution of the acid in the suitable solvent. The molar ratio between copanlisib base and the hydrochloric acid can be between1:2 and 1:2.4. The molar ratio between copanlisib and phosphoric acid (H3PO4) or malic acid can be between 1:1 and 1:1.3. The mixture is then stirred for between 10 and 60 minutes to obtain a solution. For the preparation of said salts "in situ", it is advantageous to use the corresponding acids, i.e. hydrochloric acid or malic acid or phosphoric acid (H3PO4) in an excess of 10% with respect to their stoichiometric amount needed to form the salt. The benefit of this process is the surprising simplicity of the process and economic advantage, where the "in situ" preparation eliminates yield losses due to salt isolation by crystallization or precipitation, further material handling such as separation drying and subsequent characterization. It is generally known that each crystallization step can reduce the yield by 10 to 30% (w/w).
  • The suitable solvent is preferably water. pH of the solution is preferably adjusted to pH higher than 5.5, more preferably to pH between 5.5 and 5.7, advantageously with sodium hydroxide water solution (for example 2M solution).
  • The pharmaceutical solution for lyophilization preferably contains:
    • 30 mg/ml of copanlisib (calculated as a copanlisib base) in the form of a soluble salt preferably selected from hydrochloride salt or dihydrochloride salt or hydrogen phosphate salt acid or malate salt. The salt can be added as a solid form or it can be prepared "in situ";
    • Between 20 mg/ml and 70 mg/ml bulking agent (trehalose or lactose or hydrates thereof, preferably trehalose dihydrate or lactose monohydrate); and
    • Optionally glycine in a concentration between 30 mg/ml and 60 mg/ml, preferably between 40 mg/ml and 50 mg/ml.
  • The concentration of the bulking agent in the pharmaceutical solution is preferably:
    1. i. In the case of trehalose 67.5 mg/ml (calculated on trehalose anhydrous form);
    2. ii. In the case of lactose 63.2 mg/ml (calculated on lactose anhydrous form).
  • In the case glycine is optionally used, the concentration of bulking agent trehalose or lactose is preferably between 20 mg/ml and 30 mg/ml (calculated on trehalose anhydrous form or lactose anhydrous form) and the ratio between the bulking agent and glycine can be between 2: 5 to 5: 2 (parts by weight), said ratios of excipients being calculated on the anhydrous basis and the sum of the parts by weight of the sugar component and glycine is 7.
  • The prepared pharmaceutical solution can be further processed to lyophilized injectable dosage forms as described in Examples or by a process comprising:
    1. 1. Sterile filtration of the pharmaceutical solution (through two consecutive filters with porosity of 0.2 micrometers;
    2. 2. Cleaning and depyrogenation of the vials; sterilization of the stoppers;
    3. 3. Filling and pre-closing of the vials;
    4. 4. Lyophilization and closing of the vials directly in the lyophilization chamber (under defined pressure, inert atmosphere of nitrogen can be also used);
    5. 5. Capping of the vials;
    6. 6. Visual inspection;
    7. 7. Labeling and packaging of the vials.
  • After reconstitution, for example in saline solution, the lyophilized formulation according to presented invention can be used for treatment conditions treatable by copanlisib or a salt thereof.
  • The invention will be further illustrated by the following examples.
    • EXAMPLES Reference Example 1: Lyophilized formulation prepared according to WO2019/048527 Composition of the pharmaceutical solution:
  • Copanlisib base 40.0 mg/ml
    Mannitol 80.0 mg/ml,
    Citric acid, anhydrous 3.68 mg/ml
  • 2000 mg of Mannitol was mixed with 1152 mg of copanlisib dihydrochloride, 92 mg of citric acid anhydrous and 23 mL water for injection (WFI). The mixture was sonicated for 60 seconds. Pale yellow solution was formed. pH of the solution was then adjusted using 2M NaOH to pH 4.58. Volume was made up to 25 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PVDF), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 1.71 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • In order to obtain the product without any risks of the cake collapse or any chemical degradation, the lyophilization process was conducted at the conservative parameters presented in the WO2019/048527 .
  • Thus, filled vials were loaded in in the lyophilization chamber and lyophilized using Epsilon 2-6D according to following program:
    No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar)
    1 Precooling/Loading +20 Atm.
    2 Freezing 1:20 -45 Atm.
    3 Freezing 1:30 -45 Atm.
    4 Freezing 1:00 -20 Atm.
    5 Annealing 4:00 -20 Atm.
    6 Freezing 1:10 -45 Atm.
    7 Freezing 1:00 -45 Atm.
    8 Main Drying 0:10 -45 0.100
    9 Main Drying 1:00 -5 0.100
    10 Main Drying 20:00 -5 0.100
    11 Secondary Drying 1:50 +35 0.100
    12 Secondary Drying 6:00 +35 0.100
  • In the end of the lyophilization process vials were closed under vacuum directly into the lyophilization chamber.
  • Prepared vials (after lyophilization) were put on stability study at 40 °C / 75 % R.H. Stability study results are presented in following table. Purity was determined by HPLC (Waters Alliance) with UV detection. Physical parameters were evaluated using method according to Ph. Eur. (pH, color, clarity).
  • After reconstitution with 4.4 ml of saline (0.9% NaCl), concentration of formed solution is 15 mg/ml of Copanlisib base.
    • Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1 month 2 months 3 months
    pH 4.59 4.59 4.62 4.59
    Color GY6-GY7 GY6 GY5-GY6 GY6
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I < Ref. susp. I
    Reconstitution time (seconds) 22 21 29 26
    Copanlisib base (%) 100.0 99.2 98.8 97.2
    Sum of impurities (% IN) 1.98 2.36 2.06 2.79
    • Example 2: Lyophilized formulation comprising Copanlisib dihydrochloride and trehalose Composition of the pharmaceutical solution:
  • Copanlisib base................... 30.0 mg/ml
    Trehalose .......................... 67.5 mg/ml,
  • 3746.2 mg of trehalose dihydrate was mixed with 1728 mg of copanlisib dihydrochloride and 45 mL water for injection (WFI). The mixture was sonicated for 60 seconds. Pale yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.57. Volume was made up to 50 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PVDF), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • Filled vials were loaded in in the lyophilization chamber and lyophilized using Epsilon 2-6D according to following program:
    No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar)
    1 Precooling/Loading +20 Atm.
    2 Freezing 1:20 -45 Atm.
    3 Freezing 1:30 -45 Atm.
    4 Freezing 1:00 -25 Atm.
    5 Annealing 4:00 -25 Atm.
    6 Freezing 1:30 -45 Atm.
    7 Freezing 1:00 -45 Atm.
    8 Main Drying 0:10 -45 0.100
    9 Main Drying 1:00 -20 0.100
    10 Main Drying 31:00 -20 0.100
    11 Secondary Drying 4:00 +35 0.100
    12 Secondary Drying 6:00 +35 0.100
  • In the end of the lyophilization process vials were closed under vacuum directly into the lyophilization chamber.
  • Prepared vials were put on stability study at 40 °C / 75 % R.H. Purity was determined by HPLC (Waters Alliance) with UV detection. Physical parameters were evaluated using method according to Ph. Eur. (pH, color, clarity).
  • After reconstitution with 4.4 ml of saline (0.9% NaCl), concentration of formed solution is 15 mg/ml of Copanlisib base.
    • Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1 month 2 months 3 months
    pH 5.74 5.80 5.83 5.82
    Color GY5 GY5 GY5 GY5
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I < Ref. susp. I
    Reconstitution time (seconds) 29 33 27 35
    Copanlisib base (%) 100.0 95.2 95.4 96.9
    Sum of impurities (% IN) 1.76 1.82 2.01 1.98
    • Example 3: Lyophilized formulation comprising Copanlisib dihydrochloride and lactose Composition of the pharmaceutical solution:
  • Copanlisib base 30.0 mg/ml
    Lactose 63.2 mg/ml
  • 3507.6 mg of lactose monohydrate was mixed with 1728 mg of copanlisib dihydrochloride and 40 mL water for injection (WFI), sonicated for 4 minutes. Pale yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.69. Volume was made up to 50 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PVDF), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • Filled vials were loaded in in the lyophilization chamber and lyophilized using Epsilon 2-6D according to following program:
    No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar)
    1 Precooling/Loading +20 Atm.
    2 Freezing 1:20 -45 Atm.
    3 Freezing 1:30 -45 Atm.
    4 Freezing 1:00 -18 Atm.
    5 Annealing 4:00 -18 Atm.
    6 Freezing 1:30 -45 Atm.
    7 Freezing 1:00 -45 Atm.
    8 Main Drying 0:10 -45 0.100
    9 Main Drying 1:00 -20 0.100
    10 Main Drying 31:00 -20 0.100
    11 Secondary Drying 4:00 +35 0.100
    12 Secondary Drying 6:00 +35 0.100
  • In the end of the lyophilization process vials were closed under vacuum directly into the lyophilization chamber.
  • Prepared vials were put on stability study at 40 °C / 75 % R.H. Stability study results are presented in following table. Purity was determined by HPLC (Waters Alliance) with UV detection. Physical parameters were evaluated using method according to Ph. Eur. (pH, color, clarity).
  • After reconstitution with 4.4 ml of saline (0.9% NaCl), concentration of formed solution is 15 mg/ml of Copanlisib base.
    • Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1 month 2 months 3 months
    pH 5,80 5,87 5,81 5,85
    Color GY5-GY6 GY5 GY5 GY5
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I < Ref. susp. I
    Reconstitution time (seconds) 42 34 29 35
    Copanlisib base (%) 100.0 95.2 95.4 96.9
    Sum of impurities (% IN) 1.76 1.87 2.02 1.86
    • Example 4A, 4B, 4C: Lyophilized formulation comprising copanlisib dihydrochloride, trehalose or lactose, glycine Composition of pharmaceutical solutions:
  • Example 4A Example 4B Example 4C
    Copanlisib base 30 mg/ml 30 mg/ml 30 mg/ml
    Glycine 70 mg/ml 50 mg/ml 50 mg/ ml
    Trehalose - 20 mg /ml -
    Lactose - - 20 mg/ml
  • Example 4A: 1728 mg of copanlisib dihydrochloride were mixed with 3500 mg of glycine and 30 ml of water for injection (WFI) previously bubbled with nitrogen for 20 minutes. The mixture was stirred for 15 min at 400 rpm until dissolution. Yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.60. Volume was made up to 50 mL with WFI. pH of the solution was 5.45, therefore pH was readjusted by 2 M NaOH solution to pH 5.60.
  • Solution was filtered using a 0.22-micron syringe filter (PVDF), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 4A Start 5°C/72h
    Sum of impurities (% IN) 1.24 1.16
  • Example 4B: 1728 mg of copanlisib dihydrochloride was mixed with 2500 mg of glycine, 1110 mg of trehalose dihydrate and 30 ml of water for injection (WFI) previously bubbled with nitrogen for 20 minutes. The mixture was stirred at 400 rpm for 15 minutes until dissolution. Yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.61. Volume was made up to 50 mL with WFI. pH was readjusted by 2 M NaOH solution to 5.60.
  • Solution was filtered using a 0.22-micron syringe filter (PVDF), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 4B Start 5°C/72h
    Sum of impurities (% IN) 1.24 1.22
  • Example 4C: 1728 mg of copanlisib dihydrochloride was mixed with 2500 mg of glycine, 1050 mg of lactose monohydrate and 30 ml of water for injection (WFI) previously bubbled with nitrogen for 20 minutes. The mixture was stirred at 400 rpm for 15 minutes until dissolution. Yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.60. Volume was made up to 50 mL with WFI. pH was readjusted by 2 M NaOH solution to 5.57.
  • Solution was filtered using a 0.22-micron syringe filter (PVDF), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 4C Start 5°C/72h
    Sum of impurities (% IN) 1.24 1.21
  • Vials prepared according to Examples 4A, 4B and 4C were loaded in in the lyophilization chamber and lyophilized using Epsilon 2-6D according to following program:
    No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar)
    1 Precooling/Loading +20 Atm.
    2 Freezing 2:00 -45 Atm.
    3 Freezing 1:30 -45 Atm.
    4 Freezing 1:00 -10 Atm.
    5 Annealing 4:00 -10 Atm.
    6 Freezing 1:10 -45 Atm.
    7 Freezing 1:30 -45 Atm.
    8 Main Drying 0:10 -45 0.100
    9 Main Drying 4:00 -5 0.100
    10 Main Drying 20:30 -5 0.100
    11 Secondary Drying 5:00 +35 0.100
    12 Secondary Drying 6:00 +35 0.100
  • In the end of the lyophilization process vials were closed under vacuum directly into the lyophilization chamber.
  • Prepared vials were put on stability study at 40 °C / 75 % R.H. Stability study results are presented in following table. Purity was determined by HPLC (Waters Alliance) with UV detection. Physical parameters were evaluated using method according to Ph. Eur. (pH, color, clarity).
  • After reconstitution with 4.4 ml of saline (0.9% NaCl), concentration of formed solution is 15 mg/ml of Copanlisib base.
    • Example 4A Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1 month 2 months 3 months
    pH 5.58 5.66 5.62 5.53
    Color GY5-GY6 GY5 GY5 GY5
    Clarity < Ref. susp. I Ref. susp. III Ref. susp. III Ref. susp. III
    Reconstitution time (seconds) 45 42 65 60
    Copanlisib base (%) 100.0 97.0 94.8 95.0
    Sum of impurities (% IN) 1.25 2.47 3.14 2.44
    • Example 4B Trehalose+Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1month 2 months 3 months
    pH 5.56 5.59 5.62 5.53
    Color GY5-GY6 GY6 GY5-GY6 GY5-GY6
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I < Ref. susp. I
    Reconstitution time (seconds) 53 62 22 15
    Copanlisib base (%) 100.0 100.1 95.8 95.5
    Sum of impurities (% IN) 1.24 1.48 1.36 1.42
    • Example 4C Lactose+Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1 month 2 months 3 months
    pH 5.54 5.57 5.60 5.54
    Color GY5-GY6 GY5-GY6 GY5 GY5
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I Ref. susp. II
    Reconstitution time (seconds) 52.00 22.00 18.00 28.00
    Copanlisib base (%) 100.0 98.9 96.5 97.7
    Sum of impurities (% IN) 1.40 1.51 1.46 1.40
    • Examples 5A, 5B, 5C: Lyophilized formulation comprising copanlisib hydrogenphosphate, trehalose or lactose, glycine Composition of pharmaceutical solutions:
  • Example 5A Example 5B Example 5C
    Copanlisib base 30 mg/ml 30 mg/ml 30 mg/ml
    Glycine 70 mg/ml 50 mg/ml 50 mg/ ml
    Trehalose - 20 mg /ml -
    Lactose - - 20 mg/ml
  • Example 5A: 1500 mg of copanlisib base was mixed with 3500 mg of Glycine and 20 mL of water for injection (WFI). 5 ml Phosphoric acid (H3PO4) in form of diluted solution (88 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.63. Volume was made up to 50 mL with WFI, pH was not changed.
  • Solution was filtered using a 0.22-micron syringe filter (PES), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 5A Start 5°C/72h
    Sum of impurities (% IN) 1.12 1.04
  • Example 5B: 1500 mg of copanlisib base was mixed with 2500 mg of Glycine, 1110 mg of trehalose dihydrate and 20 mL of water for injection (WFI). 5 ml of Phosphoric acid in form of diluted solution (88 mg/ml in water) was added. The mixture was stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed.
    pH of the solution was then adjusted using 2M NaOH to pH 5.67. Volume was made up to 50 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PES), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 5B Start 5°C/72h
    Sum of impurities (% IN) 1.12 1.07
  • Example 5C: 1500 mg of Copanlisib base was mixed with 2500 mg of Glycine, 1050 mg of Lactose monohydrate and 20 mL of water for injection (WFI). 5 ml of Phosphoric acid in form of diluted solution (88 mg/ml in water) was added and the mixture stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.63. Volume was made up to 50 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PES), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 5C Start 5°C/72h
    Sum of impurities (% IN) 1.12 1.10
  • Vials prepared according to Examples 5A, 5B and 5C were loaded in the lyophilization chamber and lyophilized using Christ Epsilon 2-6D according to following program:
    No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar)
    1 Precooling/Loading +20 Atm.
    2 Freezing 2:00 -45 Atm.
    3 Freezing 1:30 -45 Atm.
    4 Freezing 1:00 -10 Atm.
    5 Annealing 4:00 -10 Atm.
    6 Freezing 1:10 -45 Atm.
    7 Freezing 2:30 -45 Atm.
    8 Main Drying 0:10 -45 0.100
    9 Main Drying 4:00 -5 0.100
    10 Main Drying 20:30 -5 0.100
    11 Secondary Drying 5:00 +35 0.100
    12 Secondary Drying 6:00 +35 0.100
  • In the end of the lyophilization process vials were closed under vacuum directly into the lyophilization chamber.
  • Prepared vials were put on stability study at 40 °C / 75 % R.H. Stability study results are presented in following table. Purity was determined by HPLC (Waters Alliance) with UV detection. Physical parameters were evaluated using method according to Ph. Eur. (pH, color, clarity).
  • After reconstitution with 4.4 ml of saline (0.9% NaCl), concentration of formed solution is 15 mg/ml of Copanlisib base.
    • Example 5A Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1 month 2 months 3 months
    pH 5.80 5.72 5.72 5.79
    Color GY6-GY7 GY6 GY6 GY5-GY6
    Clarity < Ref. susp. I < Ref. susp. I Ref. susp. III Ref. susp. III
    Reconstitution time (seconds) 28 22 20 45
    Copanlisib base (%) 100.0 100.3 100.6 99.1
    Sum of impurities (% IN) 1.03 1.87 2.66 3.34
    • Examples 6A, 6B, 6C: Lyophilized formulation comprising copanlisib malate, trehalose or lactose, glycine Composition of pharmaceutical solutions:
  • Example 6A Example 6B Example 6C
    Copanlisib base 30 mg/ml 30 mg/ml 30 mg/ml
    Glycine 70 mg/ml 50 mg/ml 50 mg/ ml
    Trehalose - 20 mg /ml -
    Lactose - - 20 mg/ml
  • Example 6A: 1500 mg of Copanlisib base was mixed with 3500 mg of Glycine and 20 mL of water for injection (WFI). 5ml of Malic acid in form of diluted solution (97 mg/ml in water) was added and the mixture stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.63. Volume was made up to 50 mL with WFI. pH was readjusted by 2 M NaOH solution to 5.61.
  • Solution was filtered using a 0.22-micron syringe filter (PES), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 6A Start 5°C/72h
    Sum of impurities (% IN) 1.12 1.15
  • Example 6B: 1500 mg of copanlisib base was mixed with 2500 mg of Glycine, 1110 mg of Trehalose dihydrate and 20 mL of water for injection (WFI). 5 ml of Malic acid in form of diluted solution (97 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Pale yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.64. Volume was made up to 50 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PES), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 6B Start 5°C/72h
    Sum of impurities (% IN) 1.09 1.03
  • Example 6C: 1500 mg of Copanlisib base was mixed with 2500 mg of Glycine, 1050 mg of Lactose monohydrate and 20 mL of water for injection (WFI). 5 ml of Malic acid in form of diluted solution (97 mg/ml in water) was added and the mixture stirred for 15 minutes at 400 rpm until dissolution. Pale yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.67. Volume was made up to 50 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PES), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 6C Start 5°C/72h
    Sum of impurities (% IN) 1.12 1.04
  • Vials prepared according to Examples 6A, 6B and 6C were loaded in in the lyophilization chamber and lyophilized using Christ Epsilon 2-6D according to following program:
    No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar)
    1 Precooling/Loading +20 Atm.
    2 Freezing 2:00 -45 Atm.
    3 Freezing 1:30 -45 Atm.
    4 Freezing 1:00 -10 Atm.
    5 Annealing 4:00 -10 Atm.
    6 Freezing 1:10 -45 Atm.
    7 Freezing 2:30 -45 Atm.
    8 Main Drying 0:10 -45 0.100
    9 Main Drying 4:00 -5 0.100
    10 Main Drying 20:30 -5 0.100
    11 Secondary Drying 5:00 +35 0.100
    12 Secondary Drying 6:00 +35 0.100
  • In the end of the lyophilization process vials were closed under vacuum directly into the lyophilization chamber.
  • Prepared vials were put on stability study at 40 °C / 75 % R.H. Stability study results are presented in following table. Purity was determined by HPLC (Waters Alliance) with UV detection. Physical parameters were evaluated using method according to Ph. Eur. (pH, color, clarity).
  • After reconstitution with 4.4 ml of saline (0.9% NaCl), concentration of formed solution is 15 mg/ml of Copanlisib base.
    • Example 6A Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1 month 2 months 3 months
    pH 5.60 5.55 5.58 5,59
    Color GY6-GY7 GY6-GY7 GY5 GY5
    Clarity < Ref. susp. I Ref. susp. II-III Ref. susp. III Ref. susp. III
    Reconstitution time (seconds) 38 >10min) >10min >10min
    Copanlisib base (%) 100.0 102.4 100.1 98.5
    Sum of impurities (% IN) 0.95 1.32 1.79 2.30
    • Example 6B Trehalose+Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1month 2 months 3 months
    pH 5.57 5.52 5.53 5.53
    Color GY6-GY7 GY6-GY7 GY5-GY6 GY5
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I < Ref. susp. I
    Reconstitution time (seconds) 26 15 24 18
    Copanlisib base (%) 100.0 102.0 99.8 100.0
    Sum of impurities (% IN) 0.89 1.12 1.22 1.30
    • Example 6C Lactose+Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1 month 2 months 3 months
    pH 5.61 5.56 5.56 5.56
    Color GY6 GY6-GY7 GY5-GY6 GY5
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I < Ref. susp. I
    Reconstitution time (seconds) 28 15 32 18
    Copanlisib base (%) 100.0 101.9 99.7 99.7
    Sum of impurities (% IN) 0.92 1.14 1.23 1.14
    • Examples 7A, 7B: Lyophilized formulation comprising copanlisib hydrogenphosphate, trehalose or lactose, glycine Composition of pharmaceutical solutions:
  • Example 7A Example 7B
    Copanlisib base 30 mg/ml 30 mg/ml
    Glycine 40 mg/ml 40 mg/ ml
    Trehalose 30 mg /ml -
    Lactose - 30 mg/ml
  • Example 7A: 1500 mg of copanlisib base was mixed with 2000 mg of Glycine, 1665 mg of Trehalose dihydrate and 20 mL of water for injection (WFI). 5 ml of Phosphoric acid (H3PO4) in form of diluted solution (88 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.64. Volume was made up to 50 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PES), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 7A Start 5°C/72h
    Sum of impurities (% IN) 1.09 1.06
  • Example 7B: 1500 mg of copanlisib base was mixed with 2000 mg of Glycine, 1575 mg of Lactose and 20 mL of water for injection (WFI). 5 ml of Phosphoric acid in form of diluted solution (88 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Yellow solution was formed.
    pH of the solution was then adjusted using 2M NaOH to pH 5.66. Volume was made up to 50 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PES), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 7B Start 5°C/72h
    Sum of impurities (% IN) 1.09 1.07
  • Vials prepared according to 7A and 7B were loaded in in the lyophilization chamber and lyophilized using Christ Epsilon 2-6D according to following program:
    No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar)
    1 Precooling/Loading +20 Atm.
    2 Freezing 2:00 -45 Atm.
    3 Freezing 1:30 -45 Atm.
    4 Freezing 1:00 -10 Atm.
    5 Annealing 4:00 -10 Atm.
    6 Freezing 1:10 -45 Atm.
    7 Freezing 2:30 -45 Atm.
    8 Main Drying 0:10 -45 0.100
    9 Main Drying 4:00 -5 0.100
    10 Main Drying 20:30 -5 0.100
    11 Secondary Drying 5:00 +35 0.100
    12 Secondary Drying 6:00 +35 0.100
  • In the end of the lyophilization process vials were closed under vacuum directly into the lyophilization chamber.
  • Prepared vials were put on stability study at 40 °C / 75 % R.H. Stability study results are presented in following table. Purity was determined by HPLC (Waters Alliance) with UV detection. Physical parameters were evaluated using method according to Ph. Eur. (pH, color, clarity).
  • After reconstitution with 4.4 ml of saline (0.9% NaCl), concentration of formed solution is 15 mg/ml of Copanlisib base.
    • Example 7A Trehalose+Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1 month 2 months 3 months
    pH 5.79 5.75 5.70 5.75
    Color GY6-GY7 GY6-GY7 GY6 GY6
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I < Ref. susp. I
    Reconstitution time (seconds) 20 20 20 15
    Copanlisib base (%) 100.0 101.3 101.3 97.6
    Sum of impurities (% IN) 1.09 1.16 1.22 1.32
    • Example 7B Lactose+Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1 month 2 months 3 months
    pH 5.72 5.70 5.67 5.74
    Color GY6-GY7 GY6-GY7 GY5-GY6 GY6
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I < Ref. susp. I
    Reconstitution time (seconds) 20 20 20 20
    Copanlisib base (%) 100.0 100.7 102.0 97.9
    Sum of impurities (% IN) 1.04 1.23 1.28 1.38
    • Example 8A, 8B: Lyophilized formulation comprising copanlisib malate, trehalose or lactose, glycine Composition of pharmaceutical solutions:
  • Example 8A Example 8B
    Copanlisib base 30 mg/ml 30 mg/ml
    Glycine 40 mg/ml 40 mg/ ml
    Trehalose 30 mg /ml -
    Lactose - 30 mg/ml
  • Example 8A: 1500 mg of copanlisib base was mixed with 2000 mg of Glycine and 1665 mg of trehalose dihydrate and 20 mL of water for injection (WFI). 5 ml of Malic acid in form of diluted solution (97 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Pale yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.68. Volume was made up to 50 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PES), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 8A Start 5°C/72h
    Sum of impurities (% IN) 1.09 1.05
  • Example 8B: 1500 mg of Copanlisib base was mixed with 2000 mg of Glycine, 1575 mg of Lactose monohydrate and 20 mL of water for injection (WFI). 5 ml of Malic acid in form of diluted solution (97 mg/ml in water) was added and the mixture was stirred for 15 minutes at 400 rpm until dissolution. Pale yellow solution was formed.
  • pH of the solution was then adjusted using 2M NaOH to pH 5.71. Volume was made up to 50 mL with WFI.
  • Solution was filtered using a 0.22-micron syringe filter (PES), filled into ISO 6R vials and semi-stoppered with two leg stoppers. Filling dose was 2.28 ml per vial, overfill corresponds with 8.4 mg of Copanlisib base.
  • The pharmaceutical solution was analyzed after filtration and after 72 hours of storages at 5°C. Purity was determined by HPLC (Waters Alliance) with UV detection. No precipitation was seen in the pharmaceutical solution.
    Pharmaceutical solution 8B Start 5°C/72h
    Sum of impurities (% IN) 1.09 1.10
  • Vials prepared according to 8A and 8B were loaded in in the lyophilization chamber and lyophilized using Christ Epsilon 2-6D according to following program:
    No. Phase Time (hh:mm) Shelf (temperature °C) Vacuum (mbar)
    1 Precooling/Loading +20 Atm.
    2 Freezing 2:00 -45 Atm.
    3 Freezing 1:30 -45 Atm.
    4 Freezing 1:00 -10 Atm.
    5 Annealing 4:00 -10 Atm.
    6 Freezing 1:10 -45 Atm.
    7 Freezing 2:30 -45 Atm.
    8 Main Drying 0:10 -45 0.100
    9 Main Drying 4:00 -5 0.100
    10 Main Drying 20:30 -5 0.100
    11 Secondary Drying 5:00 +35 0.100
    12 Secondary Drying 6:00 +35 0.100
  • In the end of the lyophilization process vials were closed under vacuum directly into the lyophilization chamber.
  • Prepared vials were put on stability study at 40 °C / 75 % R.H. Stability study results are presented in following table. Purity was determined by HPLC (Waters Alliance) with UV detection. Physical parameters were evaluated using method according to Ph. Eur. (pH, color, clarity).
  • After reconstitution with 4.4 ml of saline (0.9% NaCl), concentration of formed solution is 15 mg/ml of Copanlisib base.
    • Example 8A Trehalose+Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1month 2 months 3 months
    pH 5.64 5.64 5.59 5.64
    Color GY7 GY6 GY6 GY6
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I < Ref. susp. I
    Reconstitution time (seconds) 25 19 28 18
    Copanlisib base (%) 100.0 98.9 98.7 99.1
    Sum of impurities (% IN) 1.00 1.08 1.20 1.21
    • Example 8B Lactose+Glycine: Stability study results (storage conditions 40 °C/ 75 % R.H.)
  • Sampling point Start 1month 2 months 3 months
    pH 5.61 5.62 5.55 5.66
    Color GY7 GY6 GY5-GY6 GY5-GY6
    Clarity < Ref. susp. I < Ref. susp. I < Ref. susp. I < Ref. susp. I
    Reconstitution time (seconds) 23 22 25 18
    Copanlisib base (%) 100.0 99.1 100.1 99.2
    Sum of impurities (% IN) 1.01 1.16 1.22 1.29
    • Example 7:
  • In drawing 1 the stability data of lyophilized formulations comprising copanlisib or a salt thereof and a bulking agent selected from trehalose or lactose and optionally glycine are depicted.
  • It can be concluded that stability (expressed as the change of sum of impurities in time) of lyophilized formulation according to presented invention (EX 2, EX 3, EX 4B, EX 4C, EX 5B, EX 5C, EX 6B, EX 6C) is significantly better that the stability of lyophilized formulation prepared according to prior art WO2019/048527 (Example 1, Replica in the chart).
  • In drawing 2 stabilities of formulations comprising only glycine and combination of glycine and trehalose or lactose are depicted.
  • It can be concluded that stabilities of formulation comprising glycine only (EX 5A, EX 6A) are much worse that stabilities of formulation comprising glycine and trehalose or lactose (EX 5B, EX 5C, EX 6B, EX 6C).

Claims (14)

  1. A lyophilized pharmaceutical formulation comprising:
    a. copanlisib salt
    b. a bulking agent selected from lactose or trehalose
  2. The formulation according to claim 1 wherein the salt of copanlisib is hydrochloride salt or dihydrochloride salt or hydrogen phosphate salt or malate salt.
  3. The formulation according to claims 1 or 2 further comprising glycine.
  4. The formulation according to claim 3 wherein the ratio between the bulking agent selected from lactose or trehalose and glycine is between 2:5 and 5:2 (parts by weight), said ratios of excipients being calculated on the anhydrous basis and the sum of the parts by weight of the bulking agent and glycine is 7.
  5. A process for preparation of the formulation according to claims 1 or 2 comprising:
    a. mixing the copanlisib salt with the bulking agent in a suitable solvent
    b. stirring the mixture to obtain a solution
    c. adjusting pH of the solution
    d. lyophilization of the solution
  6. A process for preparation of the formulation according to claims 1 or 2 comprising:
    a. mixing the copanlisib base with the bulking agent in a suitable solvent
    b. adding the acid
    c. stirring the mixture to obtain a solution
    d. adjusting pH of the solution
    e. lyophilization of the solution.
  7. The process according to claims 5 or 6 wherein the formulation further comprises glycine.
  8. The process according to any one of claims 5 to 7 wherein the suitable solvent is water
  9. The process according to any one of claims 5 to 8 wherein pH of the solution is adjusted to pH higher than 5.5.
  10. The process according to claim 9 wherein pH of the solution is adjusted to pH between 5.5 and 5.7.
  11. A pharmaceutical solution comprising
    a. 30 mg/ml of copanlisib salt (calculated as copanlisib base)
    b. between 20 mg/ml and 70 mg/ml of bulking agent selected from trehalose or lactose or hydrates thereof (calculated on trehalose or lactose anhydrous form)
  12. The solution according to claim 11 wherein the copanlisib salt is hydrochloride salt or dihydrochloride salt or hydrogen phosphate salt or malate salt
  13. The solution according to claims 11 or 12 further comprising glycine in a concentration between 30 mg/ml and 60 mg/ml.
  14. The solution according to claim 13 wherein the ratio between the bulking agent and glycine is between 2: 5 to 5: 2 (parts by weight), said ratios of excipients being calculated on the anhydrous basis and the sum of the parts by weight of the sugar component and glycine is 7.
EP21166992.4A 2021-04-06 2021-04-06 Lyophilized composition of copanlisib salt Active EP4070785B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP21166992.4A EP4070785B1 (en) 2021-04-06 2021-04-06 Lyophilized composition of copanlisib salt
CA3214098A CA3214098A1 (en) 2021-04-06 2022-04-01 Lyophilized composition of copanlisib salt
US18/553,911 US20240082253A1 (en) 2021-04-06 2022-04-01 Lyophilized composition of copanlisib salt
PCT/EP2022/058763 WO2022214400A1 (en) 2021-04-06 2022-04-01 Lyophilized composition of copanlisib salt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21166992.4A EP4070785B1 (en) 2021-04-06 2021-04-06 Lyophilized composition of copanlisib salt

Publications (2)

Publication Number Publication Date
EP4070785A1 true EP4070785A1 (en) 2022-10-12
EP4070785B1 EP4070785B1 (en) 2023-11-08

Family

ID=75426371

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21166992.4A Active EP4070785B1 (en) 2021-04-06 2021-04-06 Lyophilized composition of copanlisib salt

Country Status (4)

Country Link
US (1) US20240082253A1 (en)
EP (1) EP4070785B1 (en)
CA (1) CA3214098A1 (en)
WO (1) WO2022214400A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft Formulations of copanlisib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft Formulations of copanlisib

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COSTANTINO ET AL: "Excipients for use in Lyophilized Pharmaceutical Peptide, Protein, and other Bioproducts", 1 January 2005, LYOPHILIZATION OF BIOPHARMACEUTICALS,, PAGE(S) 139 - 228, ISBN: 978-0-9711767-6-8, XP008159820 *
SCHWEMANN J J ET AL: "PRACTICAL FORMULATION AND PROCESS DEVELOPMENT OF FREEZE-DRIED PRODUCTS", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, NEW YORK, NY, US, vol. 10, no. 2, 1 January 2005 (2005-01-01), pages 151 - 173, XP008048993, ISSN: 1083-7450 *

Also Published As

Publication number Publication date
US20240082253A1 (en) 2024-03-14
CA3214098A1 (en) 2022-10-13
EP4070785B1 (en) 2023-11-08
WO2022214400A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
EP0538858B1 (en) Improved lyophilized ifosfamide compositions
US10253031B2 (en) Stable pemetrexed arginine salt and compositions comprising it
EP2958554B1 (en) Stable compositions of bendamustine
CA3040018A1 (en) Pharmaceutical parenteral formulation containing carglumic acid
JP4142149B2 (en) Vancomycin lyophilized formulation
US20160256557A1 (en) Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
EP4070785B1 (en) Lyophilized composition of copanlisib salt
SK135294A3 (en) Lyophilisate preparation contains 1,1&#39;,1&#39;&#39;- -phosphinothioylindintrisaziridine and method of its production
EP2120934B1 (en) Freeze-dried injectable pharmaceutical combination of semisynthetic vinca alkaloids and carbohydrate stable at room temperature
US8481781B2 (en) Formulations of canfosfamide and their preparation
US8716521B2 (en) Formulations of canfosfamide and their preparation
WO1993007873A1 (en) Lyophilized composition containing s(+)-4,4&#39;-(1-methyl-1,2-ethanediyl)-bis(2,6-piperazinedione)
WO2024189177A1 (en) Formulation of dalbavancin
EP3031811A1 (en) Malic acid esters of bortezomib
CA2733732A1 (en) Formulations of canfosfamide and their preparation
WO2012115655A1 (en) Formulations of canfosfamide and their preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LOBL, JIRI

Inventor name: ZALUDEK, BOREK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230412

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230622

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230615

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602021006543

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1628992

Country of ref document: AT

Kind code of ref document: T

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240308

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240209

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240208

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240208

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602021006543

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20240809

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602021006543

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231108

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240406

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20240430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240406

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240430

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241105

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240430